CA2311131A1 - Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central - Google Patents
Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central Download PDFInfo
- Publication number
- CA2311131A1 CA2311131A1 CA002311131A CA2311131A CA2311131A1 CA 2311131 A1 CA2311131 A1 CA 2311131A1 CA 002311131 A CA002311131 A CA 002311131A CA 2311131 A CA2311131 A CA 2311131A CA 2311131 A1 CA2311131 A1 CA 2311131A1
- Authority
- CA
- Canada
- Prior art keywords
- adamantyl
- quinoxalinecarboxamide
- carboxamide
- quinoxaline
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Abstract
L'invention concerne des composés et des compositions pharmaceutiques contenant lesdits composés, qui agissent comme antagonistes au niveau des récepteurs du glutamate métabotropes. Lesdits composés sont utiles pour le traitement de maladies et de troubles neurologiques. Des procédés de préparation desdits composés sont également décrits.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6675897P | 1997-11-21 | 1997-11-21 | |
US60/066,758 | 1997-11-21 | ||
PCT/US1998/024833 WO1999026927A2 (fr) | 1997-11-21 | 1998-11-20 | Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2311131A1 true CA2311131A1 (fr) | 1999-06-03 |
Family
ID=22071510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002311131A Abandoned CA2311131A1 (fr) | 1997-11-21 | 1998-11-20 | Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1037878A2 (fr) |
JP (1) | JP2001524468A (fr) |
CN (2) | CN1158264C (fr) |
AU (2) | AU771358B2 (fr) |
CA (1) | CA2311131A1 (fr) |
IL (2) | IL136250A0 (fr) |
MX (1) | MXPA00004940A (fr) |
NZ (1) | NZ505207A (fr) |
WO (1) | WO1999026927A2 (fr) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1059090A4 (fr) * | 1998-03-03 | 2002-02-27 | Yamanouchi Pharma Co Ltd | Medicaments contre l'infarcissement du cerveau |
GB9823847D0 (en) * | 1998-11-02 | 1998-12-23 | Lilly Co Eli | Pharmaceutical compounds |
GB9823845D0 (en) * | 1998-11-02 | 1998-12-23 | Lilly Co Eli | Pharmaceutical compounds |
WO2000073283A1 (fr) * | 1999-06-02 | 2000-12-07 | Nps Pharmaceuticals, Inc. | Antagonistes du recepteur de glutamate metabotropique et leur utilisation pour le traitement de maladies du systeme nerveux central |
EP1210338A2 (fr) * | 1999-08-05 | 2002-06-05 | IGT Pharma Inc. | Derives de 1,4 benzodiazepine utiles dans le traitement de maladies liees au systeme nerveux central |
US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
EP1582519A3 (fr) * | 1999-08-19 | 2005-12-21 | Nps Pharmaceuticals, Inc. | Composes heteropolycycliques et leur utilisation comme antagonistes des recepteurs glutamiques metabotropes |
DK1210344T3 (da) * | 1999-08-19 | 2006-03-06 | Nps Pharma Inc | Heteropolycykliske forbindelser og anvendelser deraf som metabotrope glutamatreceptorantagonister |
CZ20021663A3 (cs) | 1999-10-15 | 2002-09-11 | F. Hoffmann-La Roche Ag | Nové deriváty benzodiazepinu |
BR0014859A (pt) * | 1999-10-15 | 2002-07-16 | Hoffmann La Roche | Derivados de benzodiazepina |
GB0007193D0 (en) * | 2000-03-25 | 2000-05-17 | Univ Manchester | Treatment of movrmrnt disorders |
DE60134762D1 (de) * | 2000-10-02 | 2008-08-21 | Janssen Pharmaceutica Nv | Metabotropische glutamatrezeptor-antagonisten |
TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
EP1430032A2 (fr) * | 2001-09-24 | 2004-06-23 | Elan Pharmaceuticals, Inc. | Amines substituees pour le traitement de la maladie d'alzheimer |
US7517517B2 (en) * | 2002-03-29 | 2009-04-14 | Janssen Pharmaceutica N.V. | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands |
CN100357283C (zh) * | 2002-04-02 | 2007-12-26 | 中国科学院上海药物研究所 | 一类甲硫氨酰氨肽酶抑制剂 |
WO2004014881A2 (fr) | 2002-08-09 | 2004-02-19 | Astra Zeneca Ab | Nouveaux composes |
WO2004056744A1 (fr) * | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides utilises comme inhibiteurs de la hydroxysteroide deshydrogenase |
US7582635B2 (en) * | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
WO2004069813A1 (fr) * | 2003-01-31 | 2004-08-19 | Astrazeneca Ab | Derives de quinoxaline satures et leur utilisation en tant que ligands du recepteur du glutamate metabotropique |
GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
RU2006106920A (ru) | 2003-08-06 | 2007-09-20 | Синомикс Инк. (Us) | Гетеро-олигомерные вкусовые рецепторы t1r, клеточные линии, которые экспрессируют указанные рецепторы и вкусовые соединения |
SE0302192D0 (sv) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
US7501416B2 (en) | 2004-02-06 | 2009-03-10 | Bristol-Myers Squibb Company | Quinoxaline compounds and methods of using them |
JP5014983B2 (ja) | 2004-05-07 | 2012-08-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 11−ベータヒドロキシステロイドデヒドロゲナーゼ阻害剤としてのピロリジン−2−オン及びピペリジン−2−オン誘導体 |
TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
EP1786774B1 (fr) | 2004-08-30 | 2009-10-14 | Janssen Pharmaceutica N.V. | Derives de lactame tricyclique utilises en tant qu'inhibiteurs de 11-beta-hydroxysteroide deshydrogenase |
DE602005017159D1 (de) | 2004-08-30 | 2009-11-26 | Janssen Pharmaceutica Nv | Oxysteroid-dehydrogenase-inhibitoren |
NZ553159A (en) * | 2004-08-30 | 2010-05-28 | Janssen Pharmaceutica Nv | N-Adamantan-2-yl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
CA2597134C (fr) | 2005-02-04 | 2015-05-26 | Senomyx, Inc. | Composes comprenant des groupements heteroaryle lies et leur utilisationa titre de nouveaux modificateurs de saveur, agents gustatifs et rehausseurs de gout umami pour compositions comestibleslimentaires |
CN101160285A (zh) | 2005-03-17 | 2008-04-09 | 辉瑞大药厂 | 适用于治疗疼痛的n-(n-磺酰氨基甲基)环丙烷甲酰胺衍生物 |
GB0506133D0 (en) * | 2005-03-24 | 2005-05-04 | Sterix Ltd | Compound |
TW200715993A (en) | 2005-06-15 | 2007-05-01 | Senomyx Inc | Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers |
EP2314574A1 (fr) | 2005-06-17 | 2011-04-27 | Apogee Biothechnology Corporation | Inhibiteurs de la sphingosine kinase |
CN101309905A (zh) * | 2005-08-12 | 2008-11-19 | 阿斯利康(瑞典)有限公司 | 取代的异吲哚酮及其作为代谢型谷氨酸受体增效剂的用途 |
US7868008B2 (en) | 2005-08-12 | 2011-01-11 | Astrazeneca Ab | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
US7807706B2 (en) | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
WO2007037543A1 (fr) * | 2005-09-29 | 2007-04-05 | Banyu Pharmaceutical Co., Ltd. | Dérivé de biarylamide |
CA2620248A1 (fr) * | 2005-10-21 | 2007-04-26 | Merz Pharma Gmbh & Co. Kgaa | Chromenones et leur utilisation en tant que modulateurs des recepteurs metabotropes au glutamate |
EP1966144A1 (fr) * | 2005-12-20 | 2008-09-10 | Novartis AG | Dérivés d'acide nicotinique en tant que modulateurs des récepteurs métabotropiques du glutamate |
TW200804281A (en) | 2006-02-16 | 2008-01-16 | Astrazeneca Ab | New metabotropic glutamate receptor-potentiating isoindolones |
DK3235811T3 (en) | 2006-04-21 | 2018-11-12 | Senomyx Inc | PROCEDURE FOR THE PREPARATION OF OXALAMIDS |
TW200817385A (en) * | 2006-07-04 | 2008-04-16 | Organon Nv | Heterocyclic derivatives |
ATE494289T1 (de) | 2006-08-04 | 2011-01-15 | Merz Pharma Gmbh & Co Kgaa | Substituierte pyrazolopyrimidine, ein verfahren zu ihrer herstellung und ihre verwendung als medizin |
CA2669915C (fr) | 2006-11-17 | 2012-02-07 | Pfizer Inc. | Composes bicyclocarboxyamides substitues |
CA2670116C (fr) | 2006-11-22 | 2015-03-10 | Seaside Therapeutics, Llc | Procedes de traitement du retard mental, du syndrome de down, du syndrome de l'x fragile et de l'autisme |
WO2008114002A1 (fr) | 2007-03-22 | 2008-09-25 | Astrazeneca Ab | Dérivés de quinoléine destinés au traitement de maladies inflammatoires |
CN101657432B (zh) | 2007-04-19 | 2013-04-10 | 弗·哈夫曼-拉罗切有限公司 | 二氢-苯并[b][1,4]二氮杂*-2-酮磺酰胺衍生物 |
TWI417100B (zh) | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | 二唑衍生物及其作為代謝型麩胺酸受體增效劑-842之用途 |
CN101348461B (zh) * | 2007-07-17 | 2011-10-05 | 西安利君制药有限责任公司 | 用于老年痴呆症治疗的n-(3-吡啶甲酰氧基)-3,5-二甲基-1-金刚烷胺或其可药用盐 |
EP2064959B1 (fr) | 2007-10-31 | 2012-07-25 | Symrise AG | Néomenthylamides aromatiques en tant qu'agents aromatisants |
PE20091036A1 (es) | 2007-11-30 | 2009-08-15 | Astrazeneca Ab | Derivado de quinolina como antagonista del receptor p2x7 |
US8211882B2 (en) * | 2008-03-08 | 2012-07-03 | Richard Delarey Wood | Glutamate receptor modulators and therapeutic agents |
US7790760B2 (en) | 2008-06-06 | 2010-09-07 | Astrazeneca Ab | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286 |
ES2432070T3 (es) | 2009-02-24 | 2013-11-29 | Respiratorius Ab | Diazaheteroarilos broncodilatadores novedosos |
WO2011109398A2 (fr) | 2010-03-02 | 2011-09-09 | President And Fellows Of Harvard College | Procédés et compositions pour le traitement du syndrome d'angelman et des troubles du spectre autistique |
US20110294879A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
WO2012006760A1 (fr) * | 2010-07-14 | 2012-01-19 | Merck Sharp & Dohme Corp. | Composés tricycliques comme modulateurs allostériques des récepteurs métabotropes au glutamate |
US20120016021A1 (en) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
CA2819034A1 (fr) * | 2010-11-30 | 2012-06-07 | Bayer Intellectual Property Gmbh | Derives pyrimidiques et leur utilisation comme agents de lutte antiparasitaire |
KR102529578B1 (ko) * | 2014-08-29 | 2023-05-09 | (주)아모레퍼시픽 | 신규 아다만탄 유도체 화합물 |
CN114539170B (zh) * | 2021-12-31 | 2023-05-16 | 华南农业大学 | 一种用于同时检测金刚烷胺、喹乙醇、氯霉素的半抗原、人工抗原及其制备方法和应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3632581A (en) * | 1968-10-08 | 1972-01-04 | American Home Prod | Schiff bases of quinoxaline-2-carboxal-dehydes and their reduction products |
GB1329447A (en) * | 1969-10-27 | 1973-09-05 | Squibb & Sons Inc | 4-adamantylaminoalkylamino-2-styryl-quinolines salts and derivatives thereof |
FR2355829A1 (fr) * | 1976-06-24 | 1978-01-20 | Debat Lab | Nouveaux derives de la nitroxoline utile en therapeutique |
IL53440A0 (en) * | 1977-11-22 | 1978-01-31 | Teva Pharma | 2-adamantyl hydrazines their preparation and pharmaceutical compositions containing them |
FR2509728A1 (fr) * | 1981-07-17 | 1983-01-21 | Roussel Uclaf | Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant |
US5346907A (en) * | 1988-04-05 | 1994-09-13 | Abbott Laboratories | Amino acid analog CCK antagonists |
IE902295A1 (en) * | 1989-07-07 | 1991-01-16 | Abbott Lab | Amino acid analog cck antagonists |
EP0669321B1 (fr) * | 1989-07-07 | 2000-09-27 | Meiji Seika Kabushiki Kaisha | Utilisation des dérivés acyloxy-4-quinoléine comme insecticides ou acaricides |
DK0480052T3 (da) * | 1990-03-28 | 1998-05-11 | Otsuka Pharma Co Ltd | Quinolinderivat, antiulcus-lægemiddel indeholdende derivatet og fremstilling af derivatet |
JPH0441425A (ja) * | 1990-06-07 | 1992-02-12 | Tanabe Seiyaku Co Ltd | 5―リポキシゲナーゼ阻害剤 |
AU4567193A (en) * | 1992-07-10 | 1994-01-31 | Laboratoires Glaxo S.A. | Anilide derivatives |
JPH07179371A (ja) * | 1993-12-21 | 1995-07-18 | Canon Inc | 液晶性化合物、それを含む液晶組成物、それを用いた液晶素子、それらを用いた表示方法、及び表示装置 |
EP0769015B1 (fr) * | 1994-07-04 | 2001-03-14 | Takeda Chemical Industries, Ltd. | Composes d'acide phosphonique, leur production et utilisation |
AU3414295A (en) * | 1994-08-19 | 1996-03-14 | Nps Pharmaceuticals, Inc. | Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases |
US5707985A (en) * | 1995-06-07 | 1998-01-13 | Tanabe Seiyaku Co. Ltd. | Naphthyl-, quinolyl- and isoquinolyl- sulfonamide derivatives as cell adhesion modulators |
JP2002501506A (ja) * | 1997-05-03 | 2002-01-15 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ドーパミンd▲下3▼受容体のモジュレーターとしてのテトラヒドロイソキノリン誘導体 |
-
1998
- 1998-11-20 WO PCT/US1998/024833 patent/WO1999026927A2/fr active Application Filing
- 1998-11-20 NZ NZ505207A patent/NZ505207A/en unknown
- 1998-11-20 CA CA002311131A patent/CA2311131A1/fr not_active Abandoned
- 1998-11-20 JP JP2000522085A patent/JP2001524468A/ja active Pending
- 1998-11-20 MX MXPA00004940A patent/MXPA00004940A/es active IP Right Grant
- 1998-11-20 CN CNB98813148XA patent/CN1158264C/zh not_active Expired - Fee Related
- 1998-11-20 CN CNA2004100474998A patent/CN1554649A/zh active Pending
- 1998-11-20 AU AU15317/99A patent/AU771358B2/en not_active Ceased
- 1998-11-20 EP EP98959535A patent/EP1037878A2/fr not_active Withdrawn
- 1998-11-20 IL IL13625098A patent/IL136250A0/xx not_active IP Right Cessation
-
2000
- 2000-05-21 IL IL136250A patent/IL136250A/en unknown
-
2004
- 2004-06-17 AU AU2004202776A patent/AU2004202776B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
NZ505207A (en) | 2003-10-31 |
AU771358B2 (en) | 2004-03-18 |
AU1531799A (en) | 1999-06-15 |
AU2004202776A1 (en) | 2004-07-22 |
AU2004202776B2 (en) | 2008-06-19 |
CN1285820A (zh) | 2001-02-28 |
JP2001524468A (ja) | 2001-12-04 |
CN1158264C (zh) | 2004-07-21 |
CN1554649A (zh) | 2004-12-15 |
WO1999026927A3 (fr) | 1999-10-21 |
IL136250A (en) | 2006-12-10 |
MXPA00004940A (es) | 2002-10-17 |
EP1037878A2 (fr) | 2000-09-27 |
AU2004202776A2 (en) | 2004-07-22 |
WO1999026927A2 (fr) | 1999-06-03 |
IL136250A0 (en) | 2001-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2311131A1 (fr) | Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central | |
US6429207B1 (en) | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | |
AU778063B2 (en) | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | |
AU2005200634A1 (en) | Tumor necrosis factor receptor-derived peptide analogues | |
US10899714B2 (en) | 6-aminoisoquinoline compounds | |
DE60033689T2 (de) | Inhibitoren von serinproteasen | |
EP0944582B1 (fr) | Cetobenzamides s'utilisant comme inhibiteurs de la calpaine | |
DE69919334T2 (de) | Phenylalaninderivate als inhibitoren von alpha4 integrinen | |
US6436925B1 (en) | Substituted benzamides, their production and their use as cysteine protease inhibitors | |
JP2020524158A (ja) | Ssao阻害剤 | |
CA2328438C (fr) | Amides substitues par voie heterocyclique, leur production et leur utilisation | |
EP0946509A1 (fr) | Nouveaux benzamides substitues de maniere heterocyclique et leur utilisation pour lutter contre des maladies | |
EP3038612B1 (fr) | Amides vinylogues cycliques en tant qu'inhibiteurs de bromodomaine | |
HRP20000788A2 (en) | Novel heterocyclically substituted amides with cysteine protease-inhibiting effect | |
DE60011940T2 (de) | Quadratsäurederivate als integrin-antagonisten | |
MXPA00000940A (en) | Haze free polyether polyol compositions and a method for their preparation | |
JPS63233972A (ja) | 新規なインドールカルボキサミド誘導体及びその塩類、それらの製造法及び中間体、これら誘導体の医薬品への使用並びにそれらを含有する組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |